Richard Clouse, MD
Family Medicine · Glasgow, KYNPI 1720078355
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Johnson & Johnson at 50.8% of the total. Reporting peaked in 2019 at $330 and has fallen 96.2% since, to $13 in 2022. That places this record below the midpoint for family medicine clinicians in KY, where the typical reported total is $656.
Across 24 payments — averaging $15.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$194
- AstraZeneca$38
- Novo Nordisk$27
- Novartis$19
- Amarin Pharma, Inc.$16
- Pear Therapeutics (US), Inc.$14
- plus $73 from 6 others
What the payments were for
- Food & beverage$381100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 10 | $194 |
| AstraZeneca | 3 | $38 |
| Novo Nordisk | 2 | $27 |
| Novartis | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $16 |
| Pear Therapeutics (US), Inc. | 1 | $14 |
| Bayer | 1 | $13 |
| Gilead | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Astellas Pharma US Inc | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $11 |
How this compares
$381 in reported general payments places this provider in the 40th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 782 | $192,873 |
| JardianceEmpagliflozin | 93 | $39,761 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $20,366 |
| XareltoRivaroxaban | 107 | $20,256 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 90 | $18,903 |
| FarxigaDapagliflozin Propanediol | 28 | $18,417 |
| MyrbetriqMirabegron | 31 | $16,473 |
| BrilintaTicagrelor | 54 | $16,236 |
| JanuviaSitagliptin Phosphate | 16 | $15,586 |
| EntrestoSacubitril/Valsartan | 116 | $11,527 |
| Divalproex Sodium | 188 | $10,933 |
| VascepaIcosapent Ethyl | 22 | $9,040 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 66 | $8,943 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 75 | $7,846 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $7,759 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $38 | $34,65382 claims |
| Johnson & JohnsonXarelto | $194 | $20,256107 claims |
| Astellas Pharma US IncMyrbetriq | $12 | $16,47331 claims |
| NovartisEntresto | $19 | $11,527116 claims |
| Novo NordiskNovolog | $27 | $2,63328 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Glasgow
- Brad MalloryGlasgow$31K
- Christopher RhyneLouisville$933K
- John RichardLexington$226K
- James TurnboPaducah$124K
- Edward SchumannFlorence$79K
- Ronald KoffNew Castle$71K
- Suraj GathaniLouisville$69K
- Bradley GrayFlorence$51K
- Jackie KazeeAshland$45K
- Mandy WhittLouisville$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.